



AnimaBiotech

ANIMA BIOTECH TO PRESENT AT THE 2nd ANNUAL RNA-TARGETED DRUG DISCOVERY SUMMIT

BERNARDSVILLE, New Jersey, December 2, 2019 – Anima Biotech, the leader in the discovery of drugs that control mRNA translation, today announced the company will present at the 2nd Annual RNA Targeted Drug Discovery Summit taking place in Boston, MA, December 2 – 4, 2019.

Yochi Slonim, Co-founder and Chief Executive Officer of Anima Biotech, will provide an overview of the company's Translation Control Therapeutics technology for the discovery of small molecule drugs that control mRNA translation. He will be available for questions and one-on-one meetings with attendees registered for the conference.

In addition to his presentation, Mr. Slonim will also participate on a "Targeting RNA with Small Molecules to Capture the Therapeutic Opportunities" panel.

Details regarding the company's presentation are as follows:

Event: 2nd Annual RNA Targeted Drug Discovery Summit

Date: Wednesday, December 4, 2019

Time: 11:00 a.m. EST

Room: Staffordshire Ballroom

Venue: The Westin Copley Place, Boston, MA, USA

Details regarding the panel discussion are as follows:

Event: Targeting RNA with Small Molecules to Capture the Therapeutic Opportunities Panel

Date: Wednesday, December 4, 2019

Time: 1:30 p.m. EST

Room: Staffordshire Ballroom

About Anima Biotech

Anima Biotech is advancing its Translation Control Platform, the first and only platform for the discovery of small molecule drugs that control mRNA translation as a new strategy against many diseases. With novel biology that monitors the translation of proteins and proprietary cloud-based analysis software, we identify drug candidates that modulate a target protein's production. We develop a pipeline across therapeutic areas and partner with Pharma for their targets including our \$1B+ collaboration with Lilly for the discovery and development of translation inhibitors of several targets. Our approach was further validated with 5 granted patents, 14 peer reviewed publications and 17 scientific collaborations. To learn more about us, visit <https://www.animabiotech.com>

###

Media Contact:

Andrew Mielach

LifeSci Public Relations

+1.646.876.5868

amielach@lifescipublicrelations.com